+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

ROI in Pharmaceutical R&D: How to Halt the Decline

  • ID: 4894603
  • Report
  • December 2019
  • Region: Global
  • 196 pages
  • BCC Research
1 of 5

FEATURED COMPANIES

  • 23Andme
  • Astellas Pharma Inc.
  • Boehringer Ingelheim Gmbh
  • Eli Lilly And Co.
  • Johnson & Johnson Inc.
  • Numerate Inc.
  • MORE
Report Scope:
The scope of this study begins with the challenges facing biotech and pharmaceutical companies today. It goes on to discuss regulatory approval processes in various countries, how these are changing, and the knock-on effects which the pharma/biotech companies will have to address. The report then reviews several key financial ratios, then discusses how to maximize clinical development success rate. We then go into how machine learning (ML) and artificial intelligence (AI), along with Big Data, are disrupting the pharma/biotech industry, in a positive way. The report then reviews the global markets for treatments for selected cancers, chronic diseases, cardiovascular disease, neurological diseases, infectious diseases and rare diseases. Chapter 15 discusses how companies need to deeply integrate ML, AI and Big Data into drug discovery and clinical testing - or risk falling behind the competition. The report wraps up with summaries of selected companies active in these spaces and beginning to utilize digital tools in R&D.

Report Includes:
  • 49 data tables and 30 additional tables
  • An assessment of return on investment (ROI) in R&D by top pharmaceutical companies within the industry
  • Analyses of the global market trends for various chronic disease areas, with data from 2016 to 2017, and projections of compound annual growth rates (CAGRs) through 2024
  • Pipeline analysis of various therapeutic drugs with oncology being the largest, and coverage of ongoing clinical trials and promising forthcoming therapies in late stage etc.
  • Outlining details of many factors involved in calculating ROI in R&D in pharma and how some of those factors are adjusted/developed to improve R&D ROI
  • Discussion of the competitive landscape and key mergers and acquisition deals, partnerships, collaborations during the timeframe, 2014-2024
  • Profile descriptions of top 15 pharmaceutical companies, their sales data, market capitalization and areas of R&D etc., including 23andMe, AstraZeneca PLC, Celgene Corp., Eli Lilly and Co., GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer Inc. and Sanofi
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 23Andme
  • Astellas Pharma Inc.
  • Boehringer Ingelheim Gmbh
  • Eli Lilly And Co.
  • Johnson & Johnson Inc.
  • Numerate Inc.
  • MORE
1. Introduction
  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Analyst's Credentials
  • Related Reports
2. Summary
  • ROI and R&D Outlays
  • Using Technology to Weed Out Losers, Focus on Potential Winners
  • Identifying Biomarkers
  • Revolutionizing Clinical Research with AI, ML and Patient Centricity
  • Global Oncology Markets by Region and Selected Types
  • Global Chronic Disease Drugs Market by Region
  • Global Cardiovascular Drugs Market by Region
  • Global Neurology Therapies Market by Region
  • Global Market for Infectious Disease Treatments by Region
  • Global Market for Orphan Drugs by Region
  • Wanted: Digitally Literate Employees Open to Continuous Learning
3. Challenges Facing Pharma and Biotech Companies
  • Strong Revenues, but Decreasing ROI
  • Tracking the Decline in ROI
  • Reasons that IRR Has Been Exceptionally Low
  • The Competitive, Expensive Search for Novel Drugs
  • Eroom’s Law
  • Emerging Global Players from India, China, Russia
  • Expiring Patents
  • Complying with Changing Regulatory Environments
  • Pricing Pressures in the US and Elsewhere
  • Traditional Structure is Blurring
  • Increasing Complexity of Clinical Trials
  • Oncology Clinical Trials Remain Complex
  • Is Oncology Research Showing the Way?
  • Patient Recruitment Consumes a Major Part of Trial Duration
  • Is the Pool of Viable New Drug Targets Diminishing?
  • The Malfunctioning Clinical Trial System
  • Solutions are Out There, and Already Working
  • The 21st Century Cures Act of 2016
  • The US FDA’s New Population Pharmacokinetics Guidance Document
  • Pharma Market Update
  • M&A Activity
  • Biotech Market Update
  • Next-Generation Biotherapeutics Pipelines Have More than Doubled
  • Biotech Pricing Pressure
  • What's Ahead
4. Regulatory Overview and New Drug Approvals
  • Improving Regulatory Compliance
  • Drug Development Continues to be Slow Process
  • Record New Drug Approvals in 2018
  • US FDA Selected Drug Approvals
  • Drug Approval Processes in the US, EMA, China, Japan
  • US FDA and the EU's EMA
  • China's Drug Regulatory Process
  • Japan's Drug Regulatory Process
5. Key Financial Ratios for Pharma and Biotech Companies
  • Return on Investment and Project-wise ROI
  • Ensuring Financial Accountability for R&D Outlays
  • Return on Research Capital (RORC)
  • Profitability Ratios
  • Liquidity and Debt Coverage Ratios
  • Return on Equity (ROE)
6. Maximizing Clinical Development Success Rates
  • Driving Change in Clinical Development
  • Utilizing Mobile Health Technologies
  • Ramping Up Real-World Data and Real-World Evidence: the FDA’s New RWE Framework
  • Maximizing Immuno-Oncology Clinical Trial Success with Immune-Related Response Criteria (irRC)
  • irRC More Useful Than RECIST for immune-oncology drugs
  • Case Study: Ipilimumab
  • Identifying Biomarkers
  • Challenges and Hurdles to Biomarker Detection and Usage
  • Use of Patient-Reported Outcomes and Pools of Prescreened Patients
  • Predictive Analytics
  • Revolutionizing Clinical Research with AI, ML and Patient Centricity
  • One Example: Patient Centricity Enabled by the Medidata Patient Cloud
  • 23andMe Wants to Solve the Patient Recruitment Problem
7. The Advantages of Being - or Acting - Small
  • Breaking Down the Silo Mentality
  • Just Say No
  • Turn on a Dime
  • Small Companies with Big Visions
  • Virgo Surgical Video Solutions
  • Ovid Therapeutics
  • Melinta Therapeutics
  • Applied Genetic Technologies
  • BioCryst Pharmaceuticals
8. The Digital Transformation of Biopharma Companies
  • Robotic Process Automation (RPA)
  • Machine Learning (ML)
  • MELLODDY (Machine Learning Ledger Orchestration for Drug Discovery) project
  • AI Lighthouse Projects: Digital Transformation Continues Apace
  • Evidation, Apple, Eli Lilly and Digital Alzheimer’s Biomarkers
  • Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium
  • DeepMind Technologies, AI and Protein Folding
  • AI For Drug Discovery and Accelerating Clinical Trials
  • Alliance for Artificial Intelligence in Healthcare (AAIH)
  • MIT’s Machine Learning for Pharmaceutical Discovery and Synthesis Consortium
  • The Challenges Found in Deploying AI
  • Healx Uses AI to Discover Rare Disease Treatments
  • Business Strategy Should Include Technology Investment
  • Empower a Cultural Change: From “Doing Digital” to “Being Digital”
  • The Implementation of Digital Trials
  • The Tortoise and the Hare
  • The Time is Now
9. Leveraging Open Innovation to Solve Development Challenges
  • Collaboration/Partnering
  • Centers of Innovation
  • J&J and Pfizer: Global Centers of Innovation
  • Germany Fosters Biopharma Innovation
  • Co-location
  • Crowdsourcing Technical and Scientific Ideas
  • Other Examples of Open Innovation in Pharma
  • Otsuka’s Collaboration with the Riken Center for Developmental Biology
  • AstraZeneca and its Center for Innovation
  • How Takeda Chose to Move Forward
  • Internal Crowd Sourcing Through Entrepreneurship Venture Program
  • External Crowd Sourcing: COCKPI-T
  • Hybrid model: Innovation Park “Shonan iPark”
10. The Global Pharma and Biotech Market for Oncology
  • Challenges in Treating Cancer
  • Clinically Significant Types of Cancers
  • Lung Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Smarter R&D Leads to More Oncology Drug Approvals
  • Global Oncology Market by Region and Selected Types
  • Global Market for Lung Cancer Chemotherapy by Region
  • Global Market for Breast Cancer Therapy by Region
  • Global Market for Ovarian Cancer Therapy by Region
11. The Global Pharma and Biotech Market for Chronic Diseases
  • Chronic Kidney Disease (CKD)
  • Background to CKD
  • Renal Disease
  • Causes of Chronic Kidney Disease
  • Incidence of End Stage Renal Disease by Country
  • Prevalence of End Stage Renal Disease by Country
  • Pharmaceutical Drugs
  • Global Market for Chronic Kidney Disease Stage 1-5 Drugs
  • Chronic Respiratory Disease Market
  • Global Diabetes Therapy Market
  • Global Chronic Gastrointestinal Market
12. The Global Pharma and Biotech Market for Cardiovascular Disease
  • Global Cardiovascular Drug Market by Region
13. The Global Pharma and Biotech Market for Neurological Diseases
  • Parkinson's Disease
  • Overview
  • Prevalence
  • Alzheimer's Disease
  • Overview
  • Prevalence
  • Schizophrenia
  • Overview
  • Prevalence
  • Bipolar Disorders
  • Overview
  • Prevalence
  • Depression
  • Overview
  • Prevalence
  • Epileptic Disorders
  • Overview
  • Prevalence
  • Autism Spectrum Disorders
  • Overview
  • Prevalence
  • Global Market for Neurology Therapies by Region
14. The Global Pharma and Biotech Market for Infectious Diseases
  • Infectious Diseases
  • Classification of Infectious Agents
  • Management of Infectious Diseases
  • Bacterial Infectious Diseases
  • Viral Infectious Diseases
  • HIV/AIDS
  • Influenza A and Influenza B
  • Risk Factors
  • Etiology and Symptoms
  • Socioeconomic Burden
  • Global Markets for Infectious Disease Treatments
  • Global Market for Infectious Disease Treatments by Region
15. The Global Pharma and Biotech Market for Rare Diseases
  • Legal Definitions of Orphan Diseases
  • Playing Games with Orphan Drug Approvals?
  • Genetically Based Tools for Rare Disease R&D
16. The Changing Future of Biopharma Work
  • Wanted: Digitally Literate Employees Open to Continuous Learning
  • Acquiring AI Capabilities Through Cloud-Based Enterprise Software with Integrated AI
17. Company Profiles
  • 23ANDME
  • ABBVIE
  • ALLERGAN PLC
  • AMGEN INC.
  • ASTELLAS PHARMA INC.
  • ASTRAZENECA PLC
  • BAYER AG
  • BIOGEN IDEC
  • BOEHRINGER INGELHEIM GMBH
  • BRISTOL-MYERS SQUIBB CO.
  • CELGENE CORP.
  • CSL BEHRING
  • ELI LILLY AND CO.
  • EXSCIENTIA
  • GILEAD SCIENCES INC.
  • GLAXOSMITHKLINE PLC
  • JOHNSON & JOHNSON INC.
  • MERCK & CO., INC.
  • NOVARTIS AG
  • NOVO NORDISK A/S
  • NUMERATE INC.
  • PFIZER INC.
  • ROCHE (F. HOFFMAN-LA ROCHE AG)
  • SANOFI
  • VERTEX PHARMACEUTICALS
18. Appendix: Acronyms

List of Tables
Summary Table: Global Market for Lung, Breast and Ovarian Cancer Therapies, by Region, Through 2024
Summary Table A: Global Chronic Disease Drugs Market, by Region, Through 2024
Summary Table B: Global Cardiovascular Drugs Market, by Region, Through 2024
Summary Table C: Global Market for Neurology Therapies, by Region, Through 2024
Summary Table D: Global Market for Infectious Disease Treatments, by Region, Through 2024
Summary Table E: Global Market for Orphan Drugs, by Region, Through 2024
Table 1: Likely Applications of AI in Pharma and Biotech Companies
Table 2: Selected M&A Deals, 2018-August 2019
Table 3: Selected US Highest-Priced Drugs
Table 4: US FDA Expedited Pathways and Other Attributes, 2017 and 2018
Table 5: US FDA Selected Drug Approvals, 2017 and 2018
Table 6: Selected FDA Orphan Drug Approvals, 2017 and 2018
Table 7: Clinical Trial Challenges and the Role of AI
Table 8: Selected Pharma Companies Utilizing AI
Table 9: Global Cancer Incidence (Both Sexes)
Table 10: Global Markets for Lung, Breast & Ovarian Cancer Therapies, by Region, Through 2024
Table 11: Global Market for Lung Cancer Chemotherapy, by Region, Through 2024
Table 12: Global Market for Breast Cancer Therapy, by Region, Through 2024
Table 13: Global Market for Ovarian Cancer Therapy, by Region, Through 2024
Table 14: Incidence of ESRD, by Country, 2015
Table 15: Prevalence of ESRD, by Country, 2015
Table 16: Global CKD 1-5 Stage Drugs Market, by Region, Through 2024
Table 17: Global Chronic Respiratory Disease Therapies Market, by Region, Through 2024
Table 18: Global Diabetes Therapy Market, by Region, Through 2024
Table 19: Global Chronic Gastrointestinal Therapy Market, by Region, Through 2024
Table 20: Global Cardiovascular Drug Market, by Region, Through 2024
Table 21: AstraZeneca PLC: Cardiovascular Pipeline
Table 22: Amgen Inc.: Cardiovascular Pipeline
Table 23: Sanofi: Cardiovascular Pipeline
Table 24: Novartis AG: Cardiovascular Pipeline
Table 25: Merck and Co., Inc.: Cardiovascular Pipeline
Table 26: Bristol-Myers Squibb Company: Cardiovascular Pipeline
Table 27: Global Market for Neurology Therapies, by Region, Through 2024
Table 28: Global Health Estimates, Leading Causes of Death, Infectious Diseases, by WHO Region, 2015
Table 29: Prevalence and Incidence of Hepatitis B, 2015
Table 30: Prevalence and Incidence of Hepatitis C, 2015
Table 31: Global Prevalence and Incidence of Genital Herpes, 2005-2015
Table 32: Prevalence of HIV, Adults (15-49 years old), by WHO Region, 2015
Table 33: New HIV Infections (per 1,000 uninfected population), Adults (15-49 years old), by WHO Region, 2015
Table 34: New HIV Infections, 2000-2030
Table 35: Years of Life Lost (YLLs), Pandemic Influenza A H1N1, by WHO Region, 2009
Table 36: Global Market for Infectious Diseases, by Product Type, Through 2024
Table 37: Global Market for Infectious Diseases, by Region, Through 2024
Table 38: Selected Country/Regional Definitions of Orphan Disease
Table 39: Description of Selected Orphan Diseases
Table 40: Global Market for Orphan Drugs, by Region, Through 2024
Table 41: Applications of AI in Pharma and Biotech Companies
Table 42: Details of Allergan's Late-Stage Pipeline, 2019
Table 43: Astellas Pharma Inc.: Selected Financials, 2016-2018
Table 44: Astellas Pharma Inc.: Marketed Products, 2018
Table 45: AstraZeneca PLC: Selected Financials, 2016-2018
Table 46: AstraZeneca PLC: Selected Marketed Products, 2018
Table 47: AstraZeneca PLC: Selected Global Product Sales, 2017 and 2018
Table 48: Bayer AG: Selected Financials, 2017 and 2018
Table 49: Biogen: Selected Financials, 2017 and 2018
Table 50: Boehringer Ingelheim GmbH: Selected Financials, 2017 and 2018
Table 51: Boehringer Ingelheim GmbH: Top 4 Human Pharmaceutical Product Sales, 2018
Table 52: Bristol-Myers Squibb Co.: Selected Financials, 2017 and 2018
Table 53: Bristol-Myers Squibb Co.: Selected Marketed Products, 2018
Table 54: Celgene Corp.: Selected Financials, 2017 and 2018
Table 55: Celgene Corp.: Selected Marketed Products, 2018
Table 56: CSL Behring: Selected Financials, 2017 and 2018
Table 57: Eli Lilly and Co.: Selected Financials, 2017 and 2018
Table 58: Eli Lilly and Co.: Selected Products
Table 59: Gilead Sciences Inc.: Selected Financials, 2017 and 2018
Table 60: Gilead Science: Selected Products and Indications
Table 61: GlaxoSmithKline PLC: Selected Financials, 2017 and 2018
Table 62: GlaxoSmithKline PLC: Selected Marketed Products
Table 63: Johnson & Johnson Inc.: Selected Financials, 2017 and 2018
Table 64: Johnson & Johnson Inc.: Selected Marketed Products, 2018
Table 65: Merck & Co., Inc.: Selected Financials, 2016-2018
Table 66: Merck & Co., Inc.: Selected Marketed Products, 2018
Table 67: Novartis AG: Net Revenue, 2017 and 2018
Table 68: Novartis AG: Selected Marketed Products, by Indication, 2018
Table 69: Novo Nordisk A/S: Net Revenue, 2017 and 2018
Table 70: Novo Nordisk A/S: Selected Products and Indications, 2018
Table 71: Pfizer Inc.: Net Revenue, 2017 and 2018
Table 72: Pfizer Inc.: Selected Products and Indications, 2018
Table 73: Roche: Net Revenue, 2017 and 2018
Table 74: Roche: Revenues from Top 10 Pharma Products, 2018
Table 75: Sanofi: Net Revenue, 2017 and 2018
Table 76: Sanofi: Selected Products and Indication, 2018
Table 77: Vertex Pharmaceuticals: Net Revenue, 2017 and 2018
Table 78: Acronyms Used in This Report

List of Figures
Summary Figure: Global Market for Lung, Breast and Ovarian Cancer Therapies, by Region, 2016-2024
  • Summary Figure A: Global Chronic Disease Drugs Market, by Region, 2016-2024
  • Summary Figure B: Global Chronic Disease Drugs Market, by Region, 2016-2024
  • Summary Figure C: Global Chronic Disease Drugs Market, by Region, 2016-2024
  • Summary Figure D: Global Chronic Disease Drugs Market, by Region, 2016-2024
  • Summary Figure E: Global Chronic Disease Drugs Market, by Region, 2016-2024
Figure 1: Selected Challenges
Figure 2: Annual Revenues of Leading Pharmaceutical Companies, 2010-2018
Figure 3: Annual Revenues of Leading Biotech Companies, 2010-2018
Figure 4: Selected Pharma Companies’ Return on R&D Spend, 2010-2018
Figure 5: Selected Pharma Companies’ R&D Spend, 2010-2018
Figure 6: Selected Biotech Companies’ R&D Spend, 2010-2018
Figure 7: Pharma/Biotech Drug Development Cycle
Figure 8: Likelihood of Approval from Phase I, by Disease Area
Figure 9: Complexity of Oncology Clinical Trials, 2010-2018
Figure 10: Number of Next-Generation Biotherapeutic Pipeline Products in Late-Stage Pipeline, 2009-2018
Figure 11: Drugs Approval Process, US FDA and EU
Figure 12: China CFDA Drug Regulatory Approval Process
Figure 13: Japan PMDA Drug Regulatory Approval Process
Figure 14: AI for Clinical Trial Design from Methodology to Improved Outcomes
Figure 15: Percentage of US and EU5 Patients Tested for Biomarker, by Cancer Type
Figure 16: Build Digital Capabilities Now
Figure 17: Annual Incidence and Mortality Data for Lung Cancer in the U.S., 1975-2015
Figure 18: Annual Incidence and Mortality Data for Lung Cancer in Five EU Countries, 1975-2012
Figure 19: Annual Incidence and Mortality Data for Breast Cancer in the U.S., 1975-2015
Figure 20: Annual Incidence and Mortality Data for Breast Cancer in Five E.U. Countries, 1975-2012
Figure 21: Annual Incidence and Mortality Data for Ovarian Cancer in the U.S., 1975-2015
Figure 22: Annual Incidence and Mortality Data for Ovarian Cancer in Five EU Countries, 1975-2012
Figure 23: Number of New Active Substance Approvals in Oncology, by Indication, 2019
Figure 24: Global Market for Lung Cancer Chemotherapy, by Region, 2016-2024
Figure 25: Global Market for Breast Cancer Therapy, by Region, 2016-2024
Figure 26: Global Market for Ovarian Cancer Therapy, by Region, 2016-2024
Figure 27: Global Cardiovascular Deaths, by Region, 2015 and 2030 (Forecast)
Figure 28: Global Health Estimates, Leading Causes of Death, Infectious Diseases, by WHO Region, 2015
Figure 29: Global Market Share of New HIV Infections, by WHO Region, 2015
Figure 30: Number of Deaths due to 2009 Pandemic Influenza A H1N1, by WHO Region, August 2009-August 2010
Figure 31: Global Market for Infectious Diseases, by Product Type, 2016-2024
Figure 32: Top 10 Pharmaceutical Companies, by Global Orphan Drug Projected Revenues, 2024
Figure 33: Global Market for Orphan Drugs, by Region, 2016-2024
Figure 34: AbbVie’s Pipeline, at the Time of Proposed Merger with Allergan, June 2019
Figure 35: Allergan Developments, 2018
Figure 36: Astellas Pharma Inc.: Revenue Share, by Region, 2018
Figure 37: Astellas Pharma Inc.: R&D Expenditure, 2017-2019 (forecast)
Figure 38: AstraZeneca PLC: Revenue Share, by Region, 2018
Figure 39: AstraZeneca PLC: Revenue Share, by Business Segment, 2018
Figure 40: AstraZeneca PLC: R&D Expenditure, 2016-2018
Figure 41: Bayer AG: Regional Sales Share, 2018
Figure 42: Boehringer Ingelheim GmbH: Revenue Share, by Region, 2018
Figure 43: Boehringer Ingelheim GmbH: Revenue Share, by Business Segment, 2018
Figure 44: Boehringer Ingelheim GmbH: R&D Expenditure, 2016-2018
Figure 45: Bristol-Myers Squibb Co.: Revenue Share, by Region, 2018
Figure 46: CSL Behring: Sales Share, by Region, FY2018 and FY2019
Figure 47: Eli Lilly and Co.: Revenue Share, by Business Segment, 2018
Figure 48: Eli Lilly and Co.: Revenue Share, by Region, 2018
Figure 49: Gilead Sciences Inc.: Revenue Share, by Region, 2018
Figure 50: GlaxoSmithKline PLC: Revenue Share, by Business Segment, 2018
Figure 51: GlaxoSmithKline PLC: Revenue Share, by Region, 2018
Figure 52: Johnson & Johnson Inc.: Revenue Share, by Business Segment, 2018
Figure 53: Johnson & Johnson Inc.: Revenue Share, by Region, 2018
Figure 54: Merck & Co., Inc.: Revenue Share, by Business Segment, 2018
Figure 55: Merck & Co., Inc.: Revenue Share, by Region, 2018
Figure 56: Novartis AG: Revenue Share, by Region, 2018
Figure 57: Novartis AG: Revenue Share, by Business Segment, 2018
Figure 58: Novo Nordisk A/S: Revenue Share, by Region, 2018
Figure 59: Novo Nordisk A/S: Revenue Share, by Business Segment, 2018
Figure 60: Pfizer Inc.: Revenue Share, by Region, 2016
Figure 61: Pfizer Inc.: Revenue Share, by Business Segment, 2018
Figure 62: Roche: Revenue Share, by Business Segment, 2018
Figure 63: Roche Pharmaceuticals: Revenue Share, by Region, 2018
Figure 64: Sanofi: Revenue Share, by Country/Region, 2018
Figure 65: Sanofi: Revenue Share, by Business Segment, 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • 23Andme
  • Astellas Pharma Inc.
  • Boehringer Ingelheim Gmbh
  • Eli Lilly And Co.
  • Johnson & Johnson Inc.
  • Numerate Inc.
  • MORE
This report investigates recent years of performance of pharmaceutical and biopharmaceutical companies with respect to return on investment (ROI) in research and development (R&D), and to discuss ways that companies are trying to improve ROI through 2024.

ROI and R&D Outlays
Many factors enter into the calculation of ROI; this is not a straightforward calculation, especially if one does not have access to the company’s internal accounting books. However, the fact that many factors enter into the calculation, also may be taken to mean that a number of factors might be adjusted or developed to improve ROI. Laying off employees is one way, but this is not effective longer-term unless the company is at the same time reorganizing for greater efficiency. Sanofi, for example, hit hard by pricing pressure in diabetes, started laying off 400 US sales employees in June 2019 but states that it is also undergoing a reorganization to its salesforce.

Using Technology to Weed Out Losers, Focus on Potential Winners

The most significant route to decreasing costs and improving failure rates is to cut off the development of a failing drug as early as possible in order to focus on potential winners. Pretty obvious - but how best to do this?

Many pharma and biotech companies are exploring the use of technology to make the most of clinical development and clinical trials. In the next three to five years:
  • Robotic automation will streamline resources across the clinical trial value chain.
  • Use of AI, ML and IT with Big Data will enable researchers to see larger trends and patterns in data, and to act on those trends earlier in the process.
  • Clinical trials will become open, and trials will be better understood by the public.
  • Clinical trials will become patient-centric and better integrated into medical systems, thereby becoming an integral part of health care.
Note: Product cover images may vary from those shown
5 of 5
  • 23Andme
  • Abbvie
  • Allergan Plc
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Astrazeneca Plc
  • Bayer Ag
  • Biogen Idec
  • Boehringer Ingelheim Gmbh
  • Bristol-Myers Squibb Co.
  • Celgene Corp.
  • CSL Behring
  • Eli Lilly And Co.
  • Exscientia
  • Gilead Sciences Inc.
  • Glaxosmithkline Plc
  • Johnson & Johnson Inc.
  • Merck & Co., Inc.
  • Novartis Ag
  • Novo Nordisk A/S
  • Numerate Inc.
  • Pfizer Inc.
  • Roche (F. Hoffman-La Roche Ag)
  • Sanofi
  • Vertex Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll